Correlation Between Viracta Therapeutics and Milestone Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Viracta Therapeutics and Milestone Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viracta Therapeutics and Milestone Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Viracta Therapeutics and Milestone Pharmaceuticals, you can compare the effects of market volatilities on Viracta Therapeutics and Milestone Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viracta Therapeutics with a short position of Milestone Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viracta Therapeutics and Milestone Pharmaceuticals.

Diversification Opportunities for Viracta Therapeutics and Milestone Pharmaceuticals

-0.38
  Correlation Coefficient

Very good diversification

The 3 months correlation between Viracta and Milestone is -0.38. Overlapping area represents the amount of risk that can be diversified away by holding Viracta Therapeutics and Milestone Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Milestone Pharmaceuticals and Viracta Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viracta Therapeutics are associated (or correlated) with Milestone Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Milestone Pharmaceuticals has no effect on the direction of Viracta Therapeutics i.e., Viracta Therapeutics and Milestone Pharmaceuticals go up and down completely randomly.

Pair Corralation between Viracta Therapeutics and Milestone Pharmaceuticals

Given the investment horizon of 90 days Viracta Therapeutics is expected to generate 2.48 times more return on investment than Milestone Pharmaceuticals. However, Viracta Therapeutics is 2.48 times more volatile than Milestone Pharmaceuticals. It trades about -0.04 of its potential returns per unit of risk. Milestone Pharmaceuticals is currently generating about -0.1 per unit of risk. If you would invest  18.00  in Viracta Therapeutics on November 2, 2024 and sell it today you would lose (2.00) from holding Viracta Therapeutics or give up 11.11% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Viracta Therapeutics  vs.  Milestone Pharmaceuticals

 Performance 
       Timeline  
Viracta Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Viracta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Viracta Therapeutics is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.
Milestone Pharmaceuticals 

Risk-Adjusted Performance

11 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Milestone Pharmaceuticals are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Milestone Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Viracta Therapeutics and Milestone Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Viracta Therapeutics and Milestone Pharmaceuticals

The main advantage of trading using opposite Viracta Therapeutics and Milestone Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viracta Therapeutics position performs unexpectedly, Milestone Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Milestone Pharmaceuticals will offset losses from the drop in Milestone Pharmaceuticals' long position.
The idea behind Viracta Therapeutics and Milestone Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Other Complementary Tools

Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Equity Valuation
Check real value of public entities based on technical and fundamental data